{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T07:43:16Z","timestamp":1722930196546},"reference-count":16,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2013,3,11]],"date-time":"2013-03-11T00:00:00Z","timestamp":1362960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ther Apher Dial"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bixalomer is a nonabsorbable polymer that binds phosphate in the gastrointestinal tract and lowers the serum phosphate level by inhibiting phosphate absorption. The safety and efficacy of long\u2010term bixalomer treatment were assessed in Japanese hemodialysis patients with hyperphosphatemia. This was a multicenter open\u2010label study with a 48\u2010week treatment period. The main efficacy endpoints were the serum phosphate level and rate of achieving the target serum phosphate range (3.5\u20136.0\u2009mg\/d<jats:styled-content style=\"fixed-case\">L<\/jats:styled-content>). Bixalomer was initiated at a dose of 1.5\u2009g\/day, which was increased to a maximum of 7.5\u2009g\/day depending on the serum phosphate response. Of 248 subjects who started treatment, 179 completed the study. The mean serum phosphate level decreased over time and remained around 5.5\u2009mg\/d<jats:styled-content style=\"fixed-case\">L<\/jats:styled-content> from weeks 16 to 48. The target serum phosphate level was reached in &gt;50% of subjects by week 7 and was maintained in 65.2% to 75.9% until week 48. The incidence of adverse events and adverse drug reactions was 94.4% and 29.4%, respectively. There was a potential relationship with the study drug for four serious adverse events (ischemic colitis, hemorrhagic intestinal diverticulum, esophageal ulcer, and acute cholecystitis), which occurred in one patient each. Constipation was the most common adverse drug reaction (21.0%). Most adverse events and adverse drug reactions occurred soon after starting administration, and their incidence did not increase during long\u2010term treatment. Bixalomer did not reduce the bicarbonate level or promote metabolic acidosis. Bixalomer is clinically useful for the long\u2010term treatment of hyperphosphatemia.<\/jats:p>","DOI":"10.1111\/1744-9987.12023","type":"journal-article","created":{"date-parts":[[2013,3,13]],"date-time":"2013-03-13T01:38:14Z","timestamp":1363138694000},"page":"612-619","source":"Crossref","is-referenced-by-count":12,"title":["Long\u2010Term Treatment of Hyperphosphatemia With Bixalomer in Japanese Hemodialysis Patients"],"prefix":"10.1111","volume":"17","author":[{"given":"Tadao","family":"Akizawa","sequence":"first","affiliation":[{"name":"Division of Nephrology Department of Medicine Showa University School of Medicine  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chisato","family":"Kameoka","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc.  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc.  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigenori","family":"Kawasaki","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc.  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Bixalomer Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,11]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000133041.27682.A2"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq582"},{"key":"e_1_2_7_4_1","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO(4), Ca\u00d7PO (4)product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"Ganesh SK","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00185.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq219"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0912522"},{"key":"e_1_2_7_8_1","first-page":"115","article-title":"Studies on the physicochemical characteristic of polymer mixed with water at the ratio of dosage and administration given to patients","volume":"28","author":"Kakuta H","year":"2012","journal-title":"Jpn J Clin Dial"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2008.00648.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.4.5893.643"},{"key":"e_1_2_7_11_1","unstructured":"Japanese Society for Dialysis Therapy.An overview of regular dialysis treatment in Japan as of Dec. 31 2010.2011."},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2002.00434.x"},{"key":"e_1_2_7_13_1","first-page":"239","article-title":"The experience of the administration of sevelamer hydrochloride to the hemodialysis patients (1): How to overcome the constipation as the adverse effect of sevelamer hydrochloride","volume":"18","author":"Hyodo T","year":"2005","journal-title":"Jpn J Urol Surg"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.09007.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00753.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00281.x"},{"key":"e_1_2_7_17_1","unstructured":"AkizawaT OrigasaH KameokaCet\u2009al.Randomized Controlled Trial of Bixalomer Versus Sevelamer Hydrochloride in Hemodialysis Patients With Hyperphosphatemia [ASN Kidney week 2011 abstract FR\u2010PO1669].2011."}],"container-title":["Therapeutic Apheresis and Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1744-9987.12023","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1744-9987.12023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:03:45Z","timestamp":1696205025000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1744-9987.12023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,11]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.1111\/1744-9987.12023"],"URL":"https:\/\/doi.org\/10.1111\/1744-9987.12023","archive":["Portico"],"relation":{},"ISSN":["1744-9979","1744-9987"],"issn-type":[{"type":"print","value":"1744-9979"},{"type":"electronic","value":"1744-9987"}],"subject":[],"published":{"date-parts":[[2013,3,11]]}}}